EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel tRF, HCETSR, Derived From tRNA‐Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1‐catenin Complex Axis

Tao Rui, Kangbei Zhu, Zonglei Mao, Jiaping Wu, Yi Pan, Qianwei Ye, Cong Chen, Aizhai Xiang, Jufeng Guo, Ning Tang, Jing Zhang, Shusen Zheng und 2 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202415229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Tao Rui und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310003, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Catenins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

tRNA‐derived fragments (tRFs), a novel class of small non‐coding RNAs cleaved from transfer RNAs, have been implicated in tumor regulation. In this study, the role of a specific tRF, HCETSR is investigated, which is significantly downregulated in hepatocellular carcinoma (HCC) and correlates with advanced tumor burden and higher HCC mortality. Functional analyses revealed that HCETSR inhibits HCC malignancy and serves as an independent predictor of poor prognosis. Mechanistically, a novel SPTBN1/catenin complex axis regulated by HCETSR is identified. HCETSR binds to a critical domain of SPTBN1, disrupting its interaction with the catenin complex (comprising β‐catenin, α‐catenin, and P120‐catenin), and facilitates the transfer of the catenin complex from the cell membrane to the nucleus. Specifically, HCETSR decreases the proteasomal degradation of β‐catenin and inhibits the synthesis of nascent β‐catenin. Furthermore, HCETSR suppresses the transcriptional activity of LEF1 through P120‐catenin rather than α‐catenin, thereby reducing β‐catenin's influence on LEF1 activity. It is demonstrated that HCETSR is spliced from tRNA‐Glu/TTC. The biogenesis of HCETSR and tRNA‐Glu/TTC is regulated by the spliceosome and Dicer1. In conclusion, These findings suggest that HCETSR, derived from tRNA‐Glu/TTC, inhibits HCC malignancy via modulation of the SPTBN1/catenin axis and may represent a promising prognostic marker and therapeutic strategy for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCateninsHumansCell Line, Tumorbeta CateninGene Expression Regulation, NeoplasticRNA, TransferMiceAnimalsMaleFemaleDelta Catenin

Stichwörter der Autor:innen

Dicer1SPTBN1catenin complexspliceosometRNA‐derived fragment

Substanzen

Cateninsbeta CateninRNA, TransferDelta Catenin

Autor:innen und Institutionen

  • Department of Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310003, China.
  • The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Department of Surgery, Collaborative Innovation Center for the Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University Hangzhou, Hangzho…
  • School of Clinical Medicine, Hangzhou Medical College, Hangzhou, 310059, China.
  • Institute of Translational Medicine, Zhejiang University, Hangzhou, 310000, China.
  • NHC Key Laboratory of Combined Multi-Organ Transplantation, Institute of Organ Transplantation, Zhejiang University, Hangzhou, 310003, China.

ORCID-Profile: Xiao Xu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China
  • Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, China

Zitieren

APA

Rui, T., Zhu, K., Mao, Z., Wu, J., Pan, Y., Ye, Q., Chen, C., Xiang, A., Guo, J., Tang, N., Zhang, J., Zheng, S., Liu, J., & Xu, X. (2025). A Novel tRF, HCETSR, Derived From tRNA‐Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1‐catenin Complex Axis. Advanced Science. https://doi.org/10.1002/advs.202415229

Vancouver

Rui T, Zhu K, Mao Z, Wu J, Pan Y, Ye Q, et al. A Novel tRF, HCETSR, Derived From tRNA‐Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1‐catenin Complex Axis. Advanced Science. 2025. doi:10.1002/advs.202415229

BibTeX
@article{Rui2025,
  author = {Rui, Tao and Zhu, Kangbei and Mao, Zonglei and Wu, Jiaping and Pan, Yi and Ye, Qianwei and Chen, Cong and Xiang, Aizhai and Guo, Jufeng and Tang, Ning and Zhang, Jing and Zheng, Shusen and Liu, Jian and Xu, Xiao},
  title = {A Novel tRF, HCETSR, Derived From tRNA‐Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1‐catenin Complex Axis},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202415229}
}
Kostenlos starten →